Autologous dendritic cell immunotherapy plus chemotherapy in metastatic castration-resistant prostate cancer
JAMA — Vogelzang NJ, Beer TM, Gerritsen W, et al. | February 14, 2022
The efficacy and safety of DCVAC/PCa, an active cellular immunotherapy, are investigated in men with metastatic castration-resistant prostate cancer (mCRPC).
A randomized clinical trial of 1,182 patients.
Overall survival (OS) did not differ between the DCVAC/PCa and placebo groups, with median OS of 23.9 and 24.3 months, respectively.
Treatment-emergent adverse events occurred in 9.2% and 12.7% of patients in DCVAC/PCa and placebo arms, respectively.
No extension in OS occurred in correlation with receiving DCVAC/PCa combined with docetaxel plus prednisone and continuing it as maintenance treatment; patients with mCRPC well tolerated the treatment.
Researchers emphasize identification of factors linked with the efficacy of immunotherapy to better select patients and thus prolong OS.